GSK is one of the first industry adopters of
the next-generation CRM as technology for commercial
innovation
PLEASANTON, Calif., Nov. 27,
2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)
today announced that GSK will be one of the first top biopharma
companies to migrate to Veeva Vault CRM. By adopting the next
generation of CRM for life sciences, GSK plans to unlock the new
technology innovation to interact with customers based on
their needs and in ways that work best for them, leading to more
effective healthcare professional (HCP) engagement.
"Data and technology are core to achieving GSK's aim to
positively impact 2.5 billion people by the end of 2030, so moving
to Vault CRM is a clear next step for us as we advance our highly
tailored HCP engagement," says Kieron
Scrutton, senior vice president of commercial and digital
technology at GSK. "Veeva deeply understands the life sciences
industry and has the expertise and vision in commercial technology
to help biopharma companies like ours bring complex therapies to
patients who need them for years to come."
Scrutton is one of the keynote speakers at Veeva Commercial
Summit, Europe. They will share
how Vault CRM is a key enabler of future commercial agility,
innovation, and differentiation.
GSK field team members rely upon Veeva's commercial applications
to expand and deepen customer relationships and launch new
medicines with efficiency and compliance. Vault CRM will include
the full functionality of market-leading Veeva CRM on the
Veeva Vault Platform, unlocking new opportunities for more
connected, customer-centric engagement across sales, medical, and
marketing. Vault CRM is part of Veeva Commercial Cloud, the
technology foundation for commercial innovation. GSK has adopted
Veeva products and services across many other areas of its
commercial and development value chains.
"Over the past decade, GSK and Veeva have built a trusted
partnership working together to advance its commercial strategy to
best support patients," said Tom
Schwenger, president and chief operating officer at Veeva.
"GSK will continue its forward-thinking approach to customer
relationships by taking full advantage of Vault CRM and future
innovations."
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information, visit
veeva.com.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and services
and the expected results or benefits from use of our products and
services, including certain of our new solutions and applications
that are still under development or not generally available. These
statements are based on our current expectations. Actual results,
availability, and any future events relating to these products and
services could differ materially from those provided in this
release and we have no obligation to update such statements. There
are numerous risks that have the potential to negatively impact our
results, including the risks and uncertainties disclosed in our
filing on Form 10-Q for the period ended July 31, 2023, which you can find here (a
summary of risks which may impact our business can be found on
pages 38 and 39), and in our subsequent SEC filings, which you can
access at sec.gov.
Contact:
|
|
Alison Borris
Veeva Systems
925-226-8821
alison.borris@veeva.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/top-biopharma-commits-to-veeva-vault-crm-for-global-customer-engagement-301997449.html
SOURCE Veeva Systems